A new trading day began on Monday, with Harvard Bioscience Inc (NASDAQ: HBIO) stock price up 4.21% from the previous day of trading, before settling in for the closing price of $1.90. HBIO’s price has ranged from $1.88 to $4.93 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company slipped by -0.32% over the past five years. Meanwhile, its annual earnings per share averaged -67.86%. With a float of $40.16 million, this company’s outstanding shares have now reached $43.62 million.
Let’s look at the performance matrix of the company that is accounted for 416 employees. In terms of profitability, gross margin is 54.26%, operating margin of -4.83%, and the pretax margin is -13.67%.
Harvard Bioscience Inc (HBIO) Insider and Institutional Ownership
As we move forward, let’s examine how large-scale investors are investing in this stock of the Medical Instruments & Supplies Industry. The insider ownership of Harvard Bioscience Inc is 7.92%, while institutional ownership is 71.96%. The most recent insider transaction that took place on Jun 13 ’24, was worth 29,100. In this transaction Chief Executive Officer of this company bought 10,000 shares at a rate of $2.91, taking the stock ownership to the 3,111,091 shares. Before that another transaction happened on Jun 06 ’24, when Company’s Chief Executive Officer bought 20,000 for $3.07, making the entire transaction worth $61,400. This insider now owns 3,101,091 shares in total.
Harvard Bioscience Inc (HBIO) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of 0.01 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -67.86% per share during the next fiscal year.
Harvard Bioscience Inc (NASDAQ: HBIO) Trading Performance Indicators
Here are Harvard Bioscience Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 0.91. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 0.88. Likewise, its price to free cash flow for the trailing twelve months is 102.81.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.33, a number that is poised to hit 0.05 in the next quarter and is forecasted to reach 0.12 in one year’s time.
Technical Analysis of Harvard Bioscience Inc (HBIO)
Harvard Bioscience Inc (NASDAQ: HBIO) saw its 5-day average volume 0.45 million, a positive change from its year-to-date volume of 0.36 million. As of the previous 9 days, the stock’s Stochastic %D was 34.15%. Additionally, its Average True Range was 0.14.
During the past 100 days, Harvard Bioscience Inc’s (HBIO) raw stochastic average was set at 11.95%, which indicates a significant decrease from 36.84% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 70.79% in the past 14 days, which was higher than the 68.37% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.2132, while its 200-day Moving Average is $2.8974. Nevertheless, the first resistance level for the watch stands at $2.0383 in the near term. At $2.0967, the stock is likely to face the second major resistance level. The third major resistance level sits at $2.2133. If the price goes on to break the first support level at $1.8633, it is likely to go to the next support level at $1.7467. The third support level lies at $1.6883 if the price breaches the second support level.
Harvard Bioscience Inc (NASDAQ: HBIO) Key Stats
With a market capitalization of 86.36 million, the company has a total of 43,617K Shares Outstanding. Currently, annual sales are 112,250 K while annual income is -3,420 K. The company’s previous quarter sales were 21,970 K while its latest quarter income was -4,800 K.
